Ligand Pharmaceuticals Incorporated
Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in its signing of an exclusive global license agreement with TG Therapeutics, Inc. (NASDAQ: TGTX) for Ligand’s Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors. Under the terms of the license, Ligand is eligible to receive $207 million in milestone payments.
TG Therapeutics is a clinical-stage biopharmaceutical company that focuses on acquiring and developing medically important pharmaceutical products for the treatment of cancer. . Ligand is a biopharmaceutical company that focuses on developing and or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. Read the press release.
San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.